
Tourmaline Bio, Inc. (NASDAQ: TRML) related to its sale to Novartis AG. Under the terms of the proposed transaction, Tourmaline shareholders will receive $48.00 in cash per share.
Tourmaline Bio, Inc. (NASDAQ: TRML) related to its sale to Novartis AG. Under the terms of the proposed transaction, Tourmaline shareholders will receive $48.00 in cash per share.